Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

181. Nexavar for Metastatic Progressive Differentiated Thyroid Carcinoma - Details

Nexavar for Metastatic Progressive Differentiated Thyroid Carcinoma - Details Nexavar for Metastatic Progressive Differentiated Thyroid Carcinoma - Details | CADTH.ca Find the information you need Nexavar for Metastatic Progressive Differentiated Thyroid Carcinoma - Details Nexavar for Metastatic Progressive Differentiated Thyroid Carcinoma - Details Project Number pCODR 10049 Brand Name Nexavar Generic Name Sorafenib Strength 200 mg tablet Tumour Type Endocrine Indication Metastatic (...) Progressive Differentiated Thyroid Carcinoma (DTC) Funding Request Treatment of patients with locally advanced or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine Review Status Notification to Implement Issued Pre Noc Submission No NOC Date June 27, 2014 Manufacturer Bayer Inc. Submitter Bayer Inc. Submission Date December 19, 2014 Submission Deemed Complete January 5, 2015 Submission Type New Indication Prioritization Requested Requested and Granted

2015 CADTH - Pan Canadian Oncology Drug Review

182. Screening and subsequent management for thyroid dysfunction pre-pregnancy and during pregnancy for improving maternal and infant health. (PubMed)

Screening and subsequent management for thyroid dysfunction pre-pregnancy and during pregnancy for improving maternal and infant health. Thyroid dysfunction pre-pregnancy and during pregnancy (both hyper- and hypothyroidism) is associated with increased risk of adverse outcomes for mothers and infants in the short- and long-term. Managing the thyroid dysfunction (e.g. thyroxine for hypothyroidism, or antithyroid medication for hyperthyroidism) may improve outcomes. The best method of screening (...) to identify and subsequently manage thyroid dysfunction pre-pregnancy and during pregnancy is unknown.To assess the effects of different screening methods (and subsequent management) for thyroid dysfunction pre-pregnancy and during pregnancy on maternal and infant outcomes.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (14 July 2015) and reference lists of retrieved studies.Randomised or quasi-randomised controlled trials, comparing any screening method (e.g. tool, program

2015 Cochrane

183. Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer (PubMed)

Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer Cervical lymph node metastases are recognized as a prognostic indicator only in patients age 45 years or older with papillary thyroid cancer (PTC); patients younger than age 45 years are perceived to have low-risk disease. The current American Joint Committee on Cancer staging for PTC in patients younger than age 45 years does not include

2015 EvidenceUpdates

184. Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. (PubMed)

Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer. Familial nonmedullary thyroid cancer accounts for 3 to 9% of all cases of thyroid cancer, but the susceptibility genes are not known. Here, we report a germline variant of HABP2 in seven affected members of a kindred with familial nonmedullary thyroid cancer and in 4.7% of 423 patients with thyroid cancer. This variant was associated with increased HABP2 protein expression in tumor samples from affected family members (...) , as compared with normal adjacent thyroid tissue and samples from sporadic cancers. Functional studies showed that HABP2 has a tumor-suppressive effect, whereas the G534E variant results in loss of function.

Full Text available with Trip Pro

2015 NEJM

185. Sorafenib (Nexavar) for Metastatic Progressive Differentiated Thyroid Carcinoma

Sorafenib (Nexavar) for Metastatic Progressive Differentiated Thyroid Carcinoma pan-Canadian Oncology Drug Review Initial Clinical Guidance Report Sorafenib (Nexavar) for Differentiated Thyroid Cancer April 30, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended to help Canadian health systems leaders and policymakers make well-informed decisions and thereby improve the quality of health care services. While patients and others may use this report (...) collectively by the provinces and territories, with the exception of Quebec, which does not participate in pCODR at this time. pCODR Initial Clinical Guidance Report – Sorafenib (Nexavar) for Differentiated Thyroid Cancer pERC Meeting: April 16, 2015 © 2015 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW ii INQUIRIES Inquiries and correspondence about the pan-Canadian Oncology Drug Review (pCODR) should be directed to: pan-Canadian Oncology Drug Review 154 University Avenue, Suite 300 Toronto, ON M5H 3Y9

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

186. Differentiated Thyroid Cancer in People Aged 85 and Older (PubMed)

Differentiated Thyroid Cancer in People Aged 85 and Older To describe the characteristics and treatment patterns of differentiated thyroid cancer in older adults.Retrospective cohort study.The National Cancer Institute Surveillance, Epidemiology, and End Results database.Individuals age 85 and older with a primary thyroid cancer diagnosis of papillary or follicular histology diagnosed between 1988 and 2007 (N=424).Age, sex, histology, extent of disease, tumor size, treatment, type of surgery (...) , cause of death, and length of survival.Tumor size and extent of disease were significantly related to cause of death (P=.02). Participants who did not have surgery were more likely to die of their thyroid cancer than of any other cause (P=.01), and whether a participant had surgery was significantly related to age (P=.002). Participants who had surgery had significantly longer survival than those who did not (P<.001). Type of surgery (P=.92) and adding radioactive iodine after surgery (P=.07) did

2015 EvidenceUpdates

187. Subclinical thyroid dysfunction and fracture risk: a meta-analysis. (PubMed)

Subclinical thyroid dysfunction and fracture risk: a meta-analysis. Associations between subclinical thyroid dysfunction and fractures are unclear and clinical trials are lacking.To assess the association of subclinical thyroid dysfunction with hip, nonspine, spine, or any fractures.The databases of MEDLINE and EMBASE (inception to March 26, 2015) were searched without language restrictions for prospective cohort studies with thyroid function data and subsequent fractures.Individual participant (...) data were obtained from 13 prospective cohorts in the United States, Europe, Australia, and Japan. Levels of thyroid function were defined as euthyroidism (thyroid-stimulating hormone [TSH], 0.45-4.49 mIU/L), subclinical hyperthyroidism (TSH <0.45 mIU/L), and subclinical hypothyroidism (TSH ≥4.50-19.99 mIU/L) with normal thyroxine concentrations.The primary outcome was hip fracture. Any fractures, nonspine fractures, and clinical spine fractures were secondary outcomes.Among 70,298 participants

Full Text available with Trip Pro

2015 JAMA

188. Lenvatinib in Radioiodine-Refractory Thyroid Cancer. (PubMed)

Lenvatinib in Radioiodine-Refractory Thyroid Cancer. 25946296 2015 05 11 2018 12 02 1533-4406 372 19 2015 05 07 The New England journal of medicine N. Engl. J. Med. Lenvatinib in radioiodine-refractory thyroid cancer. 1868 10.1056/NEJMc1503150 Lee Hyo Jin HJ Yun Hwan-Jung HJ Kim Samyong S eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Phenylurea Compounds 0 Protein Kinase Inhibitors 0 Quinolines AIM IM N Engl J Med. 2015 Feb 12;372(7):621-30 25671254 N Engl J Med. 2015 May (...) 7;372(19):1868 25946295 Female Humans Male Phenylurea Compounds therapeutic use Protein Kinase Inhibitors therapeutic use Quinolines therapeutic use Thyroid Neoplasms drug therapy 2015 5 7 6 0 2015 5 7 6 0 2015 5 12 6 0 ppublish 25946296 10.1056/NEJMc1503150 10.1056/NEJMc1503150#SA1

Full Text available with Trip Pro

2015 NEJM

189. Lenvatinib in Radioiodine-Refractory Thyroid Cancer. (PubMed)

Lenvatinib in Radioiodine-Refractory Thyroid Cancer. 25946295 2015 05 11 2018 12 02 1533-4406 372 19 2015 05 07 The New England journal of medicine N. Engl. J. Med. Lenvatinib in radioiodine-refractory thyroid cancer. 1868 10.1056/NEJMc1503150 Schlumberger Martin M Tahara Makoto M Wirth Lori J LJ eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Phenylurea Compounds 0 Protein Kinase Inhibitors 0 Quinolines AIM IM N Engl J Med. 2015 Feb 12;372(7):621-30 25671254 N Engl J Med (...) . 2015 May 7;372(19):1868 25946296 Female Humans Male Phenylurea Compounds therapeutic use Protein Kinase Inhibitors therapeutic use Quinolines therapeutic use Thyroid Neoplasms drug therapy 2015 5 7 6 0 2015 5 7 6 0 2015 5 12 6 0 ppublish 25946295 10.1056/NEJMc1503150 10.1056/NEJMc1503150#SA2

2015 NEJM

190. Screening for thyroid dysfunction: u.s. Preventive services task force recommendation statement. (PubMed)

Screening for thyroid dysfunction: u.s. Preventive services task force recommendation statement. Update of the 2004 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for thyroid disease.The USPSTF reviewed the evidence on the benefits and harms of screening for subclinical and "overt" thyroid dysfunction without clinically obvious symptoms, as well as the effects of treatment on intermediate and final health outcomes.This recommendation applies to nonpregnant (...) , asymptomatic adults.The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for thyroid dysfunction in nonpregnant, asymptomatic adults. (I statement).

Full Text available with Trip Pro

2015 Annals of Internal Medicine

191. Anti-Thyroid Peroxidase Antibodies in the General Population

Anti-Thyroid Peroxidase Antibodies in the General Population Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along (...) . It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Anti-Thyroid Peroxidase Antibodies in the General Population

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

192. Thyroid Ultrasound to Evaluate Thyroid Function

Thyroid Ultrasound to Evaluate Thyroid Function Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other (...) not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Thyroid Ultrasound to Evaluate Thyroid Function: Clinical Effectiveness

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

193. The Natural History of Benign Thyroid Nodules. (PubMed)

The Natural History of Benign Thyroid Nodules. Detection of asymptomatic thyroid nodules has increased. Consensus is lacking regarding the optimal follow-up of cytologically proven benign lesions and sonographically nonsuspicious nodules. Current guidelines recommend serial ultrasound examinations and reassessment of cytology if significant growth is observed.To determine the frequency, magnitude, and factors associated with changes in thyroid nodule size.Prospective, multicenter, observational (...) study involving 992 consecutive patients with 1 to 4 asymptomatic, sonographically or cytologically benign thyroid nodules. Patients were recruited from 8 hospital-based thyroid-disease referral centers in Italy between 2006 and 2008. Data collected during the first 5 years of follow-up, through January 2013, were analyzed.Baseline nodule growth (primary end point) was assessed with yearly thyroid ultrasound examinations. Size changes were considered significant for growth if an increase of 20

Full Text available with Trip Pro

2015 JAMA

194. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. (PubMed)

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).In our phase 3, randomized, double-blind, multicenter study involving patients (...) with progressive thyroid cancer that was refractory to iodine-131, we randomly assigned 261 patients to receive lenvatinib (at a daily dose of 24 mg per day in 28-day cycles) and 131 patients to receive placebo. At the time of disease progression, patients in the placebo group could receive open-label lenvatinib. The primary end point was progression-free survival. Secondary end points included the response rate, overall survival, and safety.The median progression-free survival was 18.3 months

Full Text available with Trip Pro

2015 NEJM

195. Cabozantinib (Cometriq) - thyroid carcinoma

Cabozantinib (Cometriq) - thyroid carcinoma AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA516) NICE GUIDANCE ISSUED FEBRUARY 2018 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Final Appraisal Recommendation Advice No: 4014 – December 2014 Cabozantinib (Cometriq ® ? ) 20 mg and 80 mg hard capsules Submission by Swedish Orphan Biovitrum Ltd/ TMC Pharma Services Ltd Additional note(s): ? AWMSG acknowledged (...) Recommendation (PAR) and the applicant company’s response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective. Recommendation of AWMSG Cabozantinib (Cometriq ® ? ) is recommended as an option for use within NHS Wales for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status

2015 All Wales Medicines Strategy Group

196. Screening and treatment of thyroid dysfunction: an evidence review for the U.S. Preventive Services Task Force. (PubMed)

Screening and treatment of thyroid dysfunction: an evidence review for the U.S. Preventive Services Task Force. In 2004, the U.S. Preventive Services Task Force found insufficient evidence to recommend thyroid screening.To update the 2004 U.S. Preventive Services Task Force review on the benefits and harms of screening and treatment of subclinical and undiagnosed overt hypothyroidism and hyperthyroidism in adults without goiter or thyroid nodules.MEDLINE and Cochrane databases through July 2014 (...) .Randomized, controlled trials and observational studies of screening and treatment.One investigator abstracted data, and a second investigator confirmed; 2 investigators independently assessed study quality.No study directly assessed benefits and harms of screening versus no screening. For subclinical hypothyroidism (based on thyroid-stimulating hormone levels of 4.1 to 11.0 mIU/L), 1 fair-quality cohort study found that treatment of subclinical hypothyroidism was associated with decreased risk

Full Text available with Trip Pro

2015 Annals of Internal Medicine

197. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee

Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee REQUESTED REVIEW Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee Onyebuchi Okosieme*, Jackie Gilbert†, Prakash Abraham‡, Kristien Boelaert§, Colin Dayan¶, Mark Gurnell**, Graham Leese††, Christopher McCabe‡‡, Petros Perros§§, Vicki Smith‡‡, Graham Williams¶¶ and Mark Vanderpump*** *Medicine, Prince Charles Hospital, Merthyr Tyd?l (...) of such individuals has been the subject of controversy and of con- siderable public interest. The American Thyroid Association (ATA) and the European Thyroid Association (ETA) have recently published guidelines on the diagnosis and management of hypothyroidism. These guidelines have been based on exten- sive reviews of the medical literature and include sections on the role of combination therapy with L-T4 and liothyronine (L-T3) in individuals who are persistently dissatis?ed with L-T4 ther- apy. This position

2015 British Thyroid Association

198. Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer - second line

Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer - second line Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer – second line Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) NIHR HSRIC. Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Vandetanib is a potent inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR) and RET tyrosine kinases. Vandetanib inhibits VEGF stimulated endothelial cell migration, proliferation, survival and new blood vessel

2015 Health Technology Assessment (HTA) Database.

199. Lenvima (lenvatinib) - To treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease)

Lenvima (lenvatinib) - To treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - LENVIMA (lenvatinib) Capsules Company: Eisai, Inc. Application No.: 206947 Approval Date: 2/13/2015 Persons with disabilities having problems

2015 FDA - Drug Approval Package

200. Thyroid Disease in Pregnancy

Thyroid Disease in Pregnancy Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2015 American College of Obstetricians and Gynecologists